These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 34962574)

  • 61. Fracture risk associated with parkinsonism and anti-Parkinson drugs.
    Vestergaard P; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2007 Sep; 81(3):153-61. PubMed ID: 17705047
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison chart: Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Dec; 62(1613):e1-e9. PubMed ID: 33647002
    [No Abstract]   [Full Text] [Related]  

  • 63. Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.
    Löhle M; Reichmann H
    BMC Neurol; 2011 Sep; 11():112. PubMed ID: 21939547
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract]   [Full Text] [Related]  

  • 65. Medical and surgical care for patients with Parkinson's disease.
    Daud DB; McDonald C
    Br J Hosp Med (Lond); 2018 Nov; 79(11):C162-C166. PubMed ID: 30418822
    [No Abstract]   [Full Text] [Related]  

  • 66. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
    Politi C; Ciccacci C; Novelli G; Borgiani P
    Neuromolecular Med; 2018 Mar; 20(1):1-17. PubMed ID: 29305687
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D
    Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
    Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
    Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Bhidayasiri R; Ling H
    J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
    Crispo JA; Fortin Y; Thibault DP; Emons M; Bjerre LM; Kohen DE; Perez-Lloret S; Mattison D; Willis AW; Krewski D
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1011-9. PubMed ID: 26081062
    [TBL] [Abstract][Full Text] [Related]  

  • 72. How should we treat a patient with early Parkinson's disease?
    Tsouli S; Konitsiotis S
    Int J Clin Pract; 2010 Aug; 64(9):1210-9. PubMed ID: 20653797
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
    Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
    Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
    Pagonabarraga J; Kulisevsky J
    Rev Neurol; 2014 Jan; 58(1):25-34. PubMed ID: 24343538
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
    Bonifati V; Meco G
    Pharmacol Ther; 1999 Jan; 81(1):1-36. PubMed ID: 10051176
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease.
    Vorovenci RJ; Antonini A
    Expert Rev Neurother; 2015; 15(12):1383-90. PubMed ID: 26630457
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
    Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
    Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.